Alto Neuroscience Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
ANRO$28.61+2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | 30,291 | 23,688 |
| General and administrative | 7,518 | 5,504 |
| Total operating expenses | 37,809 | 29,192 |
| Loss from operations | (37,809) | (29,192) |
| Other income (expense): | ||
| Interest income | 2,349 | 114 |
| Interest expense | (1,370) | — |
| Change in fair value of warrant liability | 525 | (369) |
| Grant income | — | 1,737 |
| Total other income, net | 1,504 | 1,482 |
| Net loss | $(36,305) | $(27,710) |
| Other comprehensive loss: | ||
| Foreign currency translation | (33) | (24) |
| Total other comprehensive loss | (33) | (24) |
| Comprehensive loss | $(36,338) | $(27,734) |
| Net loss per share attributable to common stockholders, basic and diluted | $(9.73) | $(8.04) |
| Weighted-average number of common shares outstanding, basic and diluted | 3,731 | 3,446 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.